Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracameral levofloxacin 0.5% vs 1.5% in cataract surgery and corneal endothelial cell density
TCTR20250919001Phase 4Not yet recruiting
- Sponsor
- Bhumibol Adulyadej Hospital Research Center
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of levofloxacin in senile cataract (ARC) (2 arms), sponsored by Bhumibol Adulyadej Hospital Research Center. Primary endpoint: Change in corneal endothelial cell density. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
levofloxacin
03
Conditions
senile cataract (ARC)
Beyond the preview
Go deeper on TCTR20250919001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20250919001.